Search results for "prostate cancer."

IS VISCERAL ADIPOSITY INDEX (VAI)RELATED TO PROSTATE CANCER DETECTED BY BIOPSY?

2014

association between obesity and prostate cancer, yielding inconsistent results. Metabolic syndrome has been suggested to promote aggressive prostate tumors. In a previous study we failed to detect a relation between Body Mass Index (BMI) and prostate cancer Gleason score (1). BMI, although routinely adopted to measure obesity, has low sensitivity and specificity. A novel sex-specific obesity index, based on waist circumference (WC), BMI, triglycerides (TGs) and high density lipoproteins (HDL), the Visceral Adiposity Index (VAI), has been proposed to estimate the visceral adiposity dysfunction (2). The aim of our preliminary research was to correlate VAI and BMI with the presence of prostate…

DES-polyacetals as polymer therapeutics for the treatment of prostate cancer

2012

Esta tesis se centra en el diseño de nuevos conjugados polímero-fármaco sensibles a pH para usarse como agentes únicos o en terapia de combinación para el tratamiento del cáncer hormono-dependiente, en particular cáncer de próstata. Éstos conjugados se basan en sístemas poliacetalicos previamente descritos en los que el fármaco forma parte de la cadena principal del polímero. En el microambiente tumoral o después de la absorción celular por endocitosis, el descenso del pH encontrado en el compartimiento ácido del endosoma lisosomal, desencadena la degradación del polímero y como consecuencia la liberación del fármaco que se difunde fuera en el citosol. Para el diseño de éstos sistemas, la n…

ADIPONECTIN, LEPTIN AND MMP-3 PLASMATIC LEVELS CANNOT IDENTIFY HIGH-RISK PROSTATE CANCER IN PATIENTS UNDERGOING BIOPSY

2016

LYCOPENE AND PROSTATE CANCER: AN OVERVIEW

2018

Prostate cancer is one of the most common cancers in the world. Its pathogenesis is multifactorial and is linked to risk factors such as age, diet, cigarette smoking, family history and the onset of oxidative stress. In recent times, therefore, we are investigating the use of antioxidants as a primary and tertuary prevention of prostate cancer. Numerous studies in the literature focused on lycopene, a molecule belonging to the family of carotenoids that is commonly foud in tomatoes and products derived from it. The literature analyzed in the last two years shows how lycopene inhibits different mecchanism linked to carcinogenesis and tumor progression. However, there are still many points to…

Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma. Twelve-year’s results of a phase II study.

2003

OBJECTIVE: To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy. PATIENTS AND METHODS: From 1983 to 1990, 41 patients with advanced prostate carcinoma were treated with flutamide monotherapy until progression or the appearance of toxicity. Twenty-five patients (61%) had T3-T4N0M0 and 16 (39%) T2-4N0-3M1 prostate carcinoma. Consensus criteria were adopted to evaluate the response. Plasma testosterone and sexual function were recorded for the first 3 years. RESULTS: Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity. There was an object…

Short and mid-term Functional Outcomes after High-intensity Ultrasound (HiFu) in the treatment of patients with localized advanced prostate cancer

2010

Vīriešu līdzestība prostatas vēža skrīningā

2019

Onkoloģisko slimību skaits ar katru gadu pieaug, tāpēc agrīnai diagnosticēšanai ir liela nozīme. Bakalaura darba tēma „Vīriešu līdzestība prostatas vēža skrīningā”. Pētījuma aktualitāti noteica statistiski apstiprināts fakts, ka prostatas vēzis ir viens no izplatītākajām onkoloģiskām slimībām Latvijā vīriešu vidū. Hipotēze: Vīriešu līdzestība prostatas vēža skrīningā būtiski ietekmē agrīnu slimības diagnosticēšanu. Darba mērķis: Noskaidrot vīriešu līdzestību prostatas vēža skrīninga programmas ietvaros. Pētījuma veikšanai izmantota kvantitatīvā pētniecības metode. Pētījuma instruments – anketa. Pētījuma rezultāti liecina, ka lielākā daļa respondentu (88%) izprot savlaicīgu diagnosticēšanas …

Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT

2021

Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC), some patients show worsening disease during PSMA-RLT. We investigated the value of combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in this setting. In n = 29 mCRPC patients with worsening disease after a median of four cycles of [177Lu]Lu-PSMA-617 RLT, combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging was performed to detect [18F]FDG-avid lesions with low or no PSMA expression (mismatch lesions). To evaluate prognostic implication of mismatch, survival analyses regarding presence, location, and [18F]FDG PET-derived para…

Characterization of the metabolic profile and identification of potential therapeutic targets in advanced prostate cancer patients

2023

INTRODUCCIÓN El cáncer de próstata (CaP) representa el segundo tumor en incidencia en hombres y es la quinta causa de muerte por cáncer a nivel global. El CaP es un tumor hormono-dependiente, que requiere de la activación del receptor de andrógenos (AR) para su proliferación. Clínicamente, se caracteriza por una gran variabilidad en su evolución, progresando desde una condición indolente hasta un fenotipo agresivo que puede diseminarse y metastatizar a los nodos linfáticos y huesos. Actualmente, el diagnóstico temprano del CaP se realiza mediante la determinación sérica del antígeno prostático específico (PSA) y el examen rectal digital (DRE). Si estas pruebas dan resultados anómalos y hay …

Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid

2007

Bisphosphonates offer a significant improvement in the quality of life for cancer patients; these potent inhibitors of bone resorption have been shown to markedly reduce the morbidity frequently resulting from bone metastases. Despite the success of bisphosphonates as therapeutic agents, however, toxicity in the form of osteonecrosis of the jaw (ONJ) is a rare complication whose incidence rate has climbed in recent years. ONJ is defined as an unexpected development of necrotic bone in the oral cavity, and is commonly associated with administration of the bisphosphonates Pamidronate and Zoledronate. Clinical features include local pain, soft-tissue swelling, and/or loose teeth; ONJ is also o…